[Advances of the Correlation between Driver Gene Status and Immunotherapy 
in Non-small Cell Lung Cancer]

Area of Science:

• Oncology
• Immunotherapy
• Genetics

Background:

• Programmed cell death 1 (PD-1) and its ligand (PD-L1) checkpoint inhibitors have advanced cancer treatment, including non-small cell lung cancer (NSCLC).
• Current immunotherapies lack precision, benefiting only 15-20% of patients and risking hyperprogression (HP).
• Predictive markers like PD-L1 expression and tumor mutation burden (TMB) have limitations for guiding treatment decisions.

Purpose of the Study:

• To explore the relationship between lung cancer-driver gene mutations and the PD-1/PD-L1 signaling pathway.
• To investigate the potential of gene mutations as predictive markers for immunotherapy efficacy in NSCLC.
• To address the need for more precise patient selection for cancer immunotherapy.

Main Methods:

• Literature review focusing on studies investigating PD-1/PD-L1 pathway, TMB, and gene mutations in NSCLC.
• Analysis of existing data correlating specific lung cancer-driver gene mutations with immunotherapy response.
• Exploration of the mechanistic links between gene mutations and aberrant PD-1/PD-L1 activation.

Main Results:

• Evidence suggests a significant correlation between specific lung cancer-driver gene mutations and the aberrant activation of the PD-1/PD-L1 signaling pathway.
• Gene mutations may play a crucial role in modulating the tumor microenvironment and response to immunotherapy.
• The limitations of current predictive markers highlight the need for novel biomarkers.

Conclusions:

• Lung cancer-driver gene mutations represent a promising area for identifying patients who will benefit from PD-1/PD-L1 targeted immunotherapy.
• Further research into the correlation between gene mutations and immunotherapy efficacy is warranted for improved patient stratification.
• Understanding these genetic links could lead to more personalized and effective cancer treatment strategies.